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Abstract
Background: In a recent pilot report, we showed that Smac/DIABLO mRNA is expressed de novo
in a subset of cervical cancer patients. We have now expanded this study and analyzed Smac/
DIABLO expression in the primary lesions in 109 cervical cancer patients.
Methods: We used immunohistochemistry of formalin-fixed, paraffin-embedded tissue sections to
analyze Smac/DIABLO expression in the 109 primary lesions. Seventy-eight samples corresponded
to epidermoid cervical cancer and 31 to cervical adenocarcinoma. The median follow up was 46.86
months (range 10–186).
Results: Smac/DIABLO was expressed in more adenocarcinoma samples than squamous tumours
(71% vs 50%; p = 0.037). Among the pathological variables, a positive correlation was found
between Smac/DIABLO immunoreactivity and microvascular density, a marker for angiogenesis (p
= 0.04). Most importantly, Smac/DIABLO immunoreactivity was associated with a higher rate of
local recurrence in squamous cell carcinoma (p = 0.002, log rank test). No association was found
between Smac/DIABLO and survival rates.
Conclusion: Smac/DIABLO expression is a potential marker for local recurrence in cervical
squamous cell carcinoma patients.
Background
Apoptosis is a type of programmed cell death morpholog-
ically characterized by membrane blebbing, nuclear and
cytoplasmic condensation and the formation of vesicles
containing intact organelles [1]. Deregulation of this proc-
ess has been implicated in numerous pathological condi-
tions including cancer. Two well-characterized apoptotic
pathways converge in caspase activation: the death recep-
tor pathway and the intrinsic or mitochondrial pathway
[2]. The intrinsic pathway is triggered by various extracel-
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lular and intracellular stresses such as growth-factor with-
drawal, hypoxia, DNA damage and oncogene induction.
These signals converge on the mitochondria, resulting in
the regulated release of cytochrome c and other proapop-
totic molecules. This leads to assembly of the apopto-
some, a complex containing cytochrome c, apoptotic
protease activating factor 1 and caspase 9. This protein
complex in turn initiates the activation of effector caspases
[3]. To avoid unregulated activation of these enzymes,
members of the Inhibitors of Apoptosis Proteins (IAPs)
family bind caspases and prevent their activation, thus
tightly controlling the induction of apoptosis [4]. In cells
undergoing apoptosis, IAPs are inactivated by interacting
with proteins containing the so-called IBM (IAP-binding
motif) [4,5]. One of these IBM proteins is the recently
identified Smac/DIABLO. Smac is a proapoptotic protein
that in healthy cells resides in the intermembrane space in
the mitochondria [6,7] but is released into the cytosol
during apoptosis, where it interacts with IAPs and disrupts
their ability to bind caspases [8]. Smac interacts with all
mammalian IAPs examined so far: XIAP, cIAP-1, cIAP-2,
survivin and ML-IAP [6,7,9,10]. In addition to its ability
to disrupt caspase inhibition by IAPs, Smac delivers cIAP1
and cIAP2 for rapid degradation by autoubiquitination
[11]. The balance of Smac/DIABLO and IAPs determines
the threshold for a variety of apoptotic stimuli.
IAPs are commonly over-expressed in human cancers [12-
14], contributing to the carcinogenic process and to the
resistance of these cells to chemotherapy [15]. However,
the importance of Smac/DIABLO, a partner in the caspase
inhibitory system, has been less well explored. Patients
with lower Smac/DIABLO levels in lung [16] and renal
[17] tumors have been shown to have worse prognoses.
This indicates that Smac expression may play a role in the
progression of several neoplastic diseases and could be
useful for prognosis. In a recent pilot report using RT-PCR,
we showed that Smac/DIABLO is expressed de novo in a
subset of cervical cancer patients [18]. The study only ana-
lyzed 41 cancer samples, precluding a more detailed anal-
ysis. In the present work we have analyzed Smac/DIABLO
expression in formalin-fixed, paraffin-embedded tissue
sections from primary lesions in 109 cervical cancer
patients.
Methods
Tumor samples
One hundred and nine cervical cancer samples were
obtained from consecutive patients recruited in the Gyne-
cological Cancer Clinic at the Instituto Nacional de Can-
cerologia of Mexico between January 1990 and December
1993. Seventy-eight corresponded to epidermoid cervical
cancer and 31 to cervical adenocarcinoma. Written con-
sent was obtained from the patients before the samples
were collected. Tumors were staged according to the Inter-
national Gynecology and Obstetric Federation (FIGO)
system. The samples comprised 6 in stage IB, 2 in IIA, 62
in IIB, 15 in IIIA and 24 in IIIB.
Histology
Histopathology was graded according to the WHO
(World Health Organization) classification system.
Immunohistochemistry
To perform immunohistochemistry, 4 μm thick sections
were obtained from archival blocks, deparaffinized and
rehydrated in graded ethanol. Antigen retrieval was done
by heating the slides (5 min in a microwave oven) in cit-
rate buffer at pH 6.0. Endogenous peroxidase activity was
blocked with 3% H2O2 for 5 min. Sections were incubated
with primary antibody at 1:75 dilution (Anti-Smac/DIA-
BLO, Calbiochem Cat: PC574) for 30 min at room tem-
perature, rinsed with PBS, and reincubated with a
secondary antibody (Rabbit Polydetector Bio SB. Cat
BSB0221) for 30 min. The peroxidase substrate was
diaminobenzidine (DAKO, Denmark). Slides were finally
counterstained with Gill's hematoxilin for 8 min. As
expected from our previous results [18], Smac/DIABLO
staining was undetectable in normal cervix (not shown).
To further validate the staining, three aleatory biopsies of
gastric carcinoma were used as positive controls, based in
a previous report showing that 70% of these tumors pre-
sented positive staining [19]. All three biopsies showed a
strong positive cytoplasmic signal. Negative controls were
included to verify specificity. The antibody used reacts
specifically with Smac/DIABLO, as verified by western
blot assays of cervical cancer cells with depleted (using an
antisense approach) or overexpressed Smac (Ceballos, G.,
submitted)
Microvessel Density (MVD)
Microvessel density was determined as described in [20].
Briefly, immunostaining for CD34 was performed in
using a monoclonal antibody (anti CD34 monoclonal
Class II, clone QBEnd/10, DAKO, Denmark) with a com-
mercial kit, as directed by the manufacturer (LSAB perox-
idase, DAKO, Denmark). Areas of cancer tissue with
distinct microvessels ("hot spots") were selected and
microvessel density was determined by counting all ves-
sels at a total magnification of 200×. All slides were eval-
uated blindly and independently by two pathologists.
Routine haematoxylin and eosin was used to evaluate
grade and lymphovascular involvement.
Evaluation of Smac/DIABLO expression
Smac/DIABLO immunoreactivity was evaluated by two
observers in a blind procedure. The slides were assessed
for intensity (0: negative, 1: less intense than positive con-
trol, 2: equal intensity to control, 3: more intense than
control) and positive area (percentage).BMC Cancer 2006, 6:256 http://www.biomedcentral.com/1471-2407/6/256
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Statistical analysis
To investigate correlations between clinical variables and
Smac/DIABLO positive immunostaining we used Chi
square tests (stage, histology and grade) and Mann-Whit-
ney tests (age, lymphovascular permeation and microvas-
cular density). Survival and recurrence were evaluated
using Kaplan-Meier curves for each variable and the curves
were compared by a log rank test. The statistical package
SPSS 12.0 was used for analyses and statistical significance
was accepted when the p value was less than 0.05.
Results
The present study included 109 patients with a mean age
of 47.14 years (range 25–73), similar to reports elsewhere
[20]. Thirty-one of them corresponded to adenocarci-
noma and 78 to squamous cell carcinoma. The median
age at diagnosis was 47 years, and the median follow up
was 46.86 months (range 10–186). The patients were
mostly in advanced stages, distributed as follows: 6 cases
corresponded to stage I, 64 to stage II and 39 to stage III.
Histologically, 11% of the samples were well differenti-
ated, 33% moderately well differentiated and 56% poorly
differentiated.
Sixty-one (56%) of the patients presented positive immu-
nostaining for Smac/DIABLO, a slightly higher percentage
that in our previous report (31.7%) [18]. Staining was pre-
dominantly cytoplasmic and involved only tumor cells;
stromal cells were negative (Fig. 1). A similar number of
samples from different stages or histopathological grades
were positive for Smac/DIABLO (Table 1). Interestingly, a
larger number of adenocarcinoma samples were Smac
immunopositive (71% vs 50%; p = 0.037) (Table 1).
Among the pathological variables, we found that positive
Smac/DIABLO samples presented a higher microvascular
density, a factor previously shown to have prognostic sig-
nificance in cervical cancer (p = 0.04) [20] (Table 2). No
other correlation was found (not shown).
To assess whether the level of Smac/DIABLO expression
correlated with the clinical variables analyzed, we pro-
duced semi quantitative scores of the immunoreactive
area and intensity (see Material and Methods). When
these scores were analyzed, we found no differences in
Photomicrographs showing Smac/DIABLO immunoreactivity in representative cervical cancer samples Figure 1
Photomicrographs showing Smac/DIABLO immunoreactivity in representative cervical cancer samples. Staining was predomi-
nantly cytoplasmic and involved only tumor cells. Left panel: low intensity (1) score. Right panel: high intensity (2) score. Total 
magnification: 400×. Procedures were performed as described in "Materials and Methods".
Table 1: Smac/DIABLO positive immunoreactivity in cervical 
cancer samples.
Variable No. patients (n = 109)* p
FIGO stage
I5  ( 8 3 ) 0 . 4 0 3
II 35 (54)
III 21 (53)
Histology of tumors
Squamous cell 39 (50) 0.037
Adenocarcinoma 22 (71)
Grade
Well differentiated 9 (75) 0.19
Moderately differentiated 22 (61)
Poorly differentiated 30 (49)
Current status
Alive 32(59) 0.121
Dead 29(53)
*Number of patients expressing Smac/DIABLO and percentage of 
positive patients in the group (in parenthesis). Chi square was used to 
test for differences. No significant differences were found when 
analyses were performed in data dichotomized for histology.BMC Cancer 2006, 6:256 http://www.biomedcentral.com/1471-2407/6/256
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clinical stage, histology or grade in neither squamous nor
adenocarcinoma samples (Table 3 and 4). Similarly,
patients with different disease status presented similar
scores (Fig. 2). When a more detailed analysis was per-
formed, we found that squamous cell carcinoma patients
with local recurrence had higher Smac/DIABLO immuno-
reactivity than non-recurrent or patients with distant
recurrences (p = 0.003) (Fig. 3) No correlation was found
for adenocarcinoma samples. To determine whether a
higher Smac/DIABLO score could predict local recurrence,
we divided the patients into two groups: low (less than 40
percent) or high (more than 40 percent) immunostained
area. Patients with squamous cancer in the high score
group recurred earlier than those in the low score group (p
= 0.002, log rank test) (Fig. 4a). No differences were found
for adenocarcinoma samples (Fig. 4b). Interestingly,
Smac/DIABLO staining intensity did not correlate with
recurrence (Fig. 4c). In addition, both high and low
immunostained area groups presented similar survival
rates and distant recurrence rates (Fig. 5).
Discussion
Apoptosis is a regulated, energy-dependent form of cell
death with a characteristic morphological appearance that
includes cellular shrinkage and chromatin condensation.
It is central to the carcinogenesis process, allowing tumors
to proliferate beyond the constraints that limit normal tis-
sue growth. The importance of alterations in apoptosis
during carcinogenesis has been confirmed by the finding
that deregulated proliferation alone is not sufficient for
tumor formation because there is concomitant induction
of cell death [21]. It has been shown that tumors com-
monly present a marked deficiency in mitochondria-
mediated apoptotic pathways. The most studied case is
exemplified by the overexpression of anti-apoptotic mem-
bers of the bcl-2 family in several malignancies [22]. A less
explored area concerns the mechanisms that regulate the
apoptotic threshold downstream of the mitochondria. In
this regard, it has been shown that IAP overexpression is a
poor prognostic marker for a variety of solid tumors and
hematological malignancies [23]. In addition, IAPs such
as survivin are being investigated as diagnostic markers for
the presence of occult malignancy [24]. In cervical cancer,
we have recently shown that XIAP and survivin are overex-
pressed and that XIAP levels correlate with relapse of this
disease [25].
Smac/DIABLO is a recently-identified proapoptotic pro-
tein that interacts with and inhibits several IAPs, including
survivin [6,9]. Smac binds to the domain of XIAP that is
Table 4: Smac/DIABLO inmmunostained area in 
adenocarcinoma samples.
Variable Median 
Smac 
score*
AD p
FIGO stage
I 54.00 27.01 0.13
II 32.72 24.01
III 20.83 19.08
Grade
Well differentiated 28.33 22.63 0.56
Moderately differentiated 39.37 219.98
Poorly differentiated 37 39.97
*Immunoreactive percentage area of Smac/DIABLO. AD: absolute 
median deviation. Kruskall-Wallis test was used to test for 
differences.
Table 2: Smac/DIABLO positive immunoreactivity in squamous 
cervical cancer samples.
Smac/DIABLO Median AD p
Age
Negative 46.58 9.17 0.621
Positive 47.52 10.6
LVP
Negative 0.51 0.72 0.479
Positive 0.39 0.63
MVD
Negative 18.02 9.7 0.047
Positive 22.93 8.93
Age, Lymphovascular Permeation (LVP) and Microvascular Density 
(MVD) values for positive and negative Smac/DIABLO patients. AD: 
Absolute Deviation. Mann-Whitney test was used to verify significant 
differences. Similar differences were found when analyses were 
performed in adenocarcinoma samples.
Table 3: Smac/DIABLO immunostained area in squamous cancer 
samples.
Variable Median Smac score* AD p
FIGO stage
I - - 0.55
II 41.25 23.64
III 33.22 17.59
Histology of tumors
Squamous cell 38.20 21.62 0.36
Adenocarcinoma 34.31 25.41
Grade
Well differentiated - - 0.46
Moderately differentiated 35.71 22.43
Poorly differentiated 39.60 21.50
* Immunoreactive percentage area of Smac/DIABLO. AD: absolute 
median deviation. Kruskall-Wallis test was used for Stage and Grade. 
Mann-Whitney was used for Histology.BMC Cancer 2006, 6:256 http://www.biomedcentral.com/1471-2407/6/256
Page 5 of 10
(page number not for citation purposes)
responsible for binding to processed caspase-9, and thus
antagonizes the anti-apoptotic function of XIAP. There is
also evidence suggesting that the pro-apoptotic function
of Smac/DIABLO could be linked to an additional mech-
anism, different from IAP binding [26]. The role of this
protein during carcinogenesis has not been widely
explored. It has been shown that Smac/DIABLO mRNA
levels are significantly lower in lung cancers than in nor-
mal tissues [16]. Patients with lower Smac/DIABLO
mRNA levels have worse prognoses. On the other hand,
Smac/DIABLO immunostaining does not correlate with disease status Figure 2
Smac/DIABLO immunostaining does not correlate with disease status. (A) and (C): Smac/DIABLO immunostained area. (B) 
and (D): Smac/DIABLO intensity of immunostaining. Scores were calculated as described in Material and Methods. Graphs 
show median, upper and lower quartiles. P value testing the significance of the difference was determined by Chi square test.BMC Cancer 2006, 6:256 http://www.biomedcentral.com/1471-2407/6/256
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Smac/DIABLO immunostaining correlates with local recurrence in squamous carcinoma Figure 3
Smac/DIABLO immunostaining correlates with local recurrence in squamous carcinoma. (A) and (C): Smac/DIABLO immunos-
tained area. (B) and (D): Smac/DIABLO intensity of immunostaining. Scores were calculated as described in Material and Meth-
ods. Graphs show median, upper and lower quartiles. P value testing the significance of the difference was determined by Chi 
square test.BMC Cancer 2006, 6:256 http://www.biomedcentral.com/1471-2407/6/256
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we recently reported that during cancer progression, a
subset of cervical tumors express this protein de novo [18].
No clinical correlations were found in that study, perhaps
reflecting a specific postraductional modulation of Smac/
DIABLO protein. Recent reports have shown that the sta-
bility of Smac/DIABLO protein is regulated by its associa-
tion with several IAPs, including XIAP [27,28], IAP1 and
IAP2 [11]. Survivin also binds to Smac/DIABLO, but it is
unable to promote ubiquitination. Since both XIAP and
survivin are overexpressed in cervical cancer [25], the level
of Smac/DIABLO expression should depend not only on
mRNA expression, but also on the balance between these
proteins and the release from mitochondria. In the
present report, we have shown for the first time that Smac/
Kaplan-Meier local recurrence estimates in cervical cancer patients by Smac/DIABLO immunostaining Figure 4
Kaplan-Meier local recurrence estimates in cervical cancer patients by Smac/DIABLO immunostaining. Squamous cell carci-
noma samples (A) or adenocarcinoma samples (B), were divided into two groups – low (less than 40 percent) or high (more 
than 40 percent) immunostained area – and plotted for local recurrence over the time shown (months). Dashed line repre-
sents cases with high Smac/DIABLO expression. A similar approach was used for the analysis of intensity of staining in squa-
mous cell carcinoma samples (C). Dashed line represents cases with high intensity. Statistical analysis was performed by log 
rank test.BMC Cancer 2006, 6:256 http://www.biomedcentral.com/1471-2407/6/256
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DIABLO protein expression correlates with local recur-
rence in cervical cancer patients.
The biological reason for this correlation is currently elu-
sive, but several mechanisms could be envisioned. Over-
expression of Smac/DIABLO could be related to cancer
progression as a response to the enhanced levels of XIAP
and survivin, probably selected positively owing to their
antiapoptotic activities. This is highly unlikely, since low
XIAP mRNA is a marker for earlier recurrence in cervical
Kaplan-Meier survival estimates in cervical cancer patients by Smac/DIABLO immunoreactive scores Figure 5
Kaplan-Meier survival estimates in cervical cancer patients by Smac/DIABLO immunoreactive scores. Patients were divided 
into two groups – low (less than 40) or high (more than 40) scores – and plotted for survival (A and B) or distant recurrence 
(C and D) over the time shown (months). Dashed line represents cases with high Smac/DIABLO expression. Statistical analysis 
was performed by log rank test.BMC Cancer 2006, 6:256 http://www.biomedcentral.com/1471-2407/6/256
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cancer patients [25]. This decrease could have a similar
effect to larger amounts of Smac/DIABLO, as in the
present report, so it patients with low XIAP would also be
expected to have higher Smac/DIABLO expression. Analy-
ses of both proteins in the same panel of patients should
help to clarify this. An alternative explanation for the
increased incidence of local recurrence in squamous cell
carcinoma patients with high Smac/DIABLO immunore-
activity could be related to the recent finding that Smac
binds to NADE, a component of the TRAIL death receptor
protein complex [29]. In TRAIL-resistant cancer cells, acti-
vation of the receptor for this factor leads to a NF-kappa
B-mediated increase in tumor invasion and metastasis
instead of cell death [30]. Since direct interaction of Smac/
DIABLO with NADE potentiates the signal from the TRAIL
receptor, higher Smac expression could lead to an
increased invasive potential in resistant cells. Further anal-
ysis of the prevalence of TRAIL resistance in cervical
tumors should help to clarify this.
An additional contradictory result was the finding of the
association of Smac/DIABLO expression with the rate of
local recurrence, but not with survival or distant recur-
rence. Since apoptosis suppression is an important
requirement for metastasis, Smac expression could be ren-
dering cervical cancer cells more susceptible to cell death
in circulation or, alternatively, to foreign micro ambient
compartments, thus counterbalancing the effect of
increased local recurrence in prognosis. Supporting this
idea, a recent report has shown that XIAP, the main Smac/
DIABLO target, is a negative regulator of anoikis of circu-
lating prostate cancer cells [31]. Additional analyses using
transgenic cell lines in animal models should help to val-
idate this hypothesis.
Another interesting observation was that the correlation
of Smac/DIABLO with local recurrence was restricted to
squamous cell carcinoma patients. It has been previously
shown that both histological types represent different
pathological entities, since adenocarcinoma tumors have
poorer prognoses, metastasize more easily to lymph
nodes and are more resistant to radiotherapy than squa-
mous cell tumors [32-34]. From these observations, we
can expect important biological differences that could
potentially explain our data.
One final interesting finding was the association between
Smac/DIABLO levels and microvascular density (MVD).
Previous reports have shown that MVD is poor prognosis
factor in cervical cancer patients [20]. Patients with MVD
higher than 20 presented a higher risk of recurrence. Since
Smac/DIABLO immunoreactivity was associated with
higher MVD, the early recurrence seen in our patients
could be due to enhanced angiogenesis. No published
reports have explored the effect of Smac/DIABLO overex-
pression on the synthesis of pro-angiogenic molecules, or
vice versa, although the association of Smac with signal
transduction complexes [29,35] and the activation of the
NF-kappa B pathway could provide a possible mechanism
for the synthesis of angiogenic molecules.
Conclusion
The present report shows that high Smac/DIABLO immu-
noreactivity is associated with a higher rate of recurrence
in cervical squamous cell carcinoma patients. In addition,
Smac/DIABLO expression correlated positively with
microvascular density in these patients. Further studies
directed at elucidating the role of Smac/DIABLO in the
recurrence and invasion of cervical cancer are clearly
needed.
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